CL2023003191A1 - Novedosas composiciones y métodos de n,n-dimetiltriptamina - Google Patents

Novedosas composiciones y métodos de n,n-dimetiltriptamina

Info

Publication number
CL2023003191A1
CL2023003191A1 CL2023003191A CL2023003191A CL2023003191A1 CL 2023003191 A1 CL2023003191 A1 CL 2023003191A1 CL 2023003191 A CL2023003191 A CL 2023003191A CL 2023003191 A CL2023003191 A CL 2023003191A CL 2023003191 A1 CL2023003191 A1 CL 2023003191A1
Authority
CL
Chile
Prior art keywords
dmt
dimethyltryptamine
methods
novel compositions
exhibiting
Prior art date
Application number
CL2023003191A
Other languages
English (en)
Inventor
Glenn Short
Srinivas Rao
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of CL2023003191A1 publication Critical patent/CL2023003191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición que incluye N,N-dimetiltriptamina (DMT) o una sal farmacéuticamente aceptable de esta capaz de exhibir un nivel sanguíneo terapéuticamente efectivo de DMT de entre aproximadamente 20 y aproximadamente 60 minutos cuando se administra a un ser humano. Un método para tratar una enfermedad o afección neurológica que comprende administrar por vía bucal, sublingual, subcutánea o intranasal a un sujeto que lo necesita una cantidad efectiva de DMT o una sal farmacéuticamente aceptable de esta, capaz de exhibir un nivel terapéuticamente efectivo de DMT de entre aproximadamente 20 a aproximadamente 60 minutos cuando se administra a un ser humano.
CL2023003191A 2021-04-26 2023-10-25 Novedosas composiciones y métodos de n,n-dimetiltriptamina CL2023003191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
CL2023003191A1 true CL2023003191A1 (es) 2024-04-01

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003191A CL2023003191A1 (es) 2021-04-26 2023-10-25 Novedosas composiciones y métodos de n,n-dimetiltriptamina

Country Status (12)

Country Link
US (1) US11602521B2 (es)
EP (1) EP4329879A1 (es)
JP (1) JP2024517738A (es)
KR (1) KR20240000516A (es)
CN (1) CN117320711A (es)
AU (1) AU2022267240A1 (es)
BR (1) BR112023022195A2 (es)
CA (1) CA3216889A1 (es)
CL (1) CL2023003191A1 (es)
IL (1) IL308074A (es)
MX (1) MX2023012651A (es)
WO (1) WO2022232179A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
AU2022425541A1 (en) 2021-12-30 2024-06-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023186827A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
TW202423415A (zh) * 2022-10-26 2024-06-16 美商雅特益醫療公司 Ｎ－ｎ－二甲基色胺（ｄｍｔ）及ｄｍｔ類似物組合物、其製造方法及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US20220031662A1 (en) 2019-02-22 2022-02-03 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
CR20210437A (es) 2019-02-22 2021-11-02 Gh Res Ireland Limited 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3146050A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2022061242A1 (en) 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement

Also Published As

Publication number Publication date
JP2024517738A (ja) 2024-04-23
US20220339139A1 (en) 2022-10-27
WO2022232179A9 (en) 2023-07-13
EP4329879A1 (en) 2024-03-06
WO2022232179A1 (en) 2022-11-03
CA3216889A1 (en) 2022-11-03
IL308074A (en) 2023-12-01
CN117320711A (zh) 2023-12-29
MX2023012651A (es) 2023-11-06
AU2022267240A1 (en) 2023-11-23
KR20240000516A (ko) 2024-01-02
BR112023022195A2 (pt) 2024-01-16
US11602521B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
CL2023003191A1 (es) Novedosas composiciones y métodos de n,n-dimetiltriptamina
US7115252B2 (en) Therapeutic compositions and methods of use thereof
Padmini et al. Oral and dental considerations in pediatric leukemic patient
ATE304850T1 (de) Verfahren zur stiegerung des blutglukosespiegels in säugern
JP2020128437A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
RU2550957C1 (ru) Способ лечения хронического генерализованного пародонтита
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
Stecker et al. Should a mucoadhesive patch (DentiPatch) be used for gingival anesthesia in children?
Bansal et al. Comparative evaluation of coronally advanced flap with and without bioactive glass putty in the management of gingival recession defects: a randomized controlled clinical trial
Sacco et al. The treatment of periodontal disease using local oxygen-ozone
Eftimoska et al. Comparative study of caries removal using BRIX 3000 and classic mechanical method
US20040116521A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
WO2000018380A1 (en) Prevention and treatment of parodontitis
AR122160A1 (es) PROCEDIMIENTO PARA EL TRATAMIENTO DE UNA INFECCIÓN VIRAL CON a-1-ANTITRIPSINA HUMANA
RU2624867C1 (ru) Способ комплексного лечения больных с воспалительными заболеваниями пародонта
Al-Zarea et al. Efficacy of Myrrh Mouth Rinse vs. Chlorhexidine Mouth Rinse in Maintaining the Soft Tissue Health around Dental Implants: A Comparative Study.
RU2605260C1 (ru) Способ комплексного лечения больных с воспалительными заболеваниями пародонта
US20070020200A1 (en) Therapeutic compositions and methods of use thereof
RU2705388C1 (ru) Способ лечения хронического генерализованного катарального гингивита
RU2772298C1 (ru) Способ лечения хронического катарального гингивита с применением антисептической композиции
da Silva Lemos et al. Sci Forschen
RU2643589C1 (ru) Способ лечения острого неспецифического гингивита и хронического гингивита маргинального простого
Poulose et al. A comparative study of Apamarga Kshara Lepa and Jaloukavacharana in the management of Dushta Vrana